跳轉至內容
Merck
全部照片(1)

Key Documents

G003762

HPLC Analysis of Piroxicam and 2-Aminopyridine in Urine on Discovery® HS F5 after SPE using Discovery® DSC-MCAX

application for SPE, application for HPLC

登入查看組織和合約定價


About This Item

技術

HPLC: suitable
solid phase extraction (SPE): suitable

測試參數

sample preparation: SPE (Solid Phase Extraction)
sample/matrix: human urine spiked with piroxicam (4 μg/mL) and 2-aminopyridine (10 μg/mL)
SPE tube/cartridge: Discovery DSC-MCAX, 100 mg/3 mL (52783-U)
condition: 1 mL methanol; 1 mL 10 mM potassium phosphate, pH 3
sample addition: 1 mL
washing: 1 mL 10 mM potassium phosphate, pH 3; 1 mL methanol
elution: 1 mL 5% ammonium hydroxide in methanol
eluate post-treatment: evaporate to dryness with nitrogen at room temperature, reconstitute in 1 mL mobile phase
column: Discovery HS F5, 15 cm x 4.6 mm I.D., 5 μm particles (567516-U)
mobile phase: [A] 10 mM potassium phosphate, pH 6: [B] acetonitrile (85:15, A:B)
flow rate: 2 mL/min
column temp.: 25 °C
detector: UV, 220 nm
injection: 10 μL

適合性

application for HPLC
application for SPE

應用

clinical

應用

Sample Pre-Treatment:
Piroxicam and 2-aminopyridine (piroxicam′s polar metabolite) was spiked into human urine at the levels of 4 and 10 μg/mL, respectively. The urine sample was diluted 1:1 with 10 mM potassium phosphate, pH 3.

法律資訊

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務